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Abstract
Metabolic syndrome, insulin resistance, prediabetes, and overt type 2 diabetes mellitus are
associated with an accelerated atherosclerosis (atheroscleropathy). This quartet is also associated
with multiple metabolic toxicities resulting in the production of reactive oxygen species. The redox
stress associated with these reactive oxygen species contribute to the development, progression,
and the final fate of the arterial vessel wall in prediabetic and diabetic atheroscleropathy. The
prevention of morbidity and mortality of these intersecting metabolic diseases can be approached
through comprehensive global risk reduction.
Introduction
Metabolic syndrome (MS), insulin resistance (IR), predia-
betes (PD), and overt type 2 diabetes mellitus (T2DM)
amplifies and accelerates the risk of atherosclerosis with
its associated effect on morbidity and mortality.
The multiple toxicities of this quartet: MS, IR, PD which
includes impaired glucose tolerance (IGT) and impaired
fasting glucose (IFG), and overt T2DM result in accelerat-
ed atherosclerosis (macrovascular disease) or atheroscle-
ropathy in addition to microvascular disease. It is
appropriate to set forth definitions for this discussion.
Definition
Working definition of atherosclerosis:
Atherosclerosis is a systemic dysfunctional endothelial, fo-
cal occurring, chronic inflammatory, fibroprolifertive, an-
giogenic, prothrombotic, multifactorial disease of the
arterial intima caused by the retention of modified low
density lipoproteins, hemodynamic, and redox stress [1–
4] (figure 1) (figure 2).
Working definition of atheroscleropathy:
Atheroscleropathy: The term used to describe the unique ac-
celerated atherosclerosis observed in and associated with
MS, IR, PD, and overt T2DM.            
Henceforth, in this review the term atheroscleropathy shall
be used to describe accelerated atherosclerosis associated
with MS, IR, PD, and overt T2DM.
Three quarters of a century ago, a quote from Elliott P Jos-
lin's presentation to the American College of Physicians in
1927 seems appropriate.
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Figure 1
An anatomical pull out image of each layer of the arterial vessel wall. The intima colored light blue is the location of the primary
remodeling including the positive outward and later in time the negative inward remodeling with encroachment of the lumen.
The inward negative remodeling is associated more with stable angina and stable plaques. The positive outward remodeling is
associated more with unstable coronary syndromes and unstable VPs and has a much higher level of MMP-3 (stromelysin-ase)
activity which may be increased as is MMP-9 in the diabetic patients. It is the MMPs which allow the tearing down (remodeling)
in order for the outward remodeling to occur. See section on Redox Stress and MMP activity.Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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Figure 2
This image portrays the anatomical relationships of the endothelium, intima, media, and adventitia. Each of these layers play an
important role in the development of atheroscleropathy. Since the discovery of the essential role of an intact endothelium for
the vasomotor control of musculo-elastic arteries by Furchgott and Zawadski in 1980, and the discovery of the NOSs in 1989,
the endothelium has been found to play a central role in the maintenance of healthy arteries and found to be placed in a central
role for the development and progression of atherogenesis and subsequent atheroscleropathy. The endothelium is five times
the weight of the heart and equal to the weight of the liver. This organ is placed at a critical location as an interface with nutri-
ents and toxic products not only at its luminal side of musculo-eleastic arteries but also at the endothelial extracellular matrix
interface at the site of capillaries. This exciting monolayer of unique cells is responsible for the production of a gas NO that
acts to modulate blood flow and is a naturally occurring interfacing antioxidant capable of scavenging ROS. The intima, sand-
wiched between the internal elastic lamina of the medial smooth muscle cell layer and the endothelium is the site of atheroscle-
rosis, intimopathy, and the atheroscleropathy associated with MS, IR, PD, and T2DM. The injurious stimuli depicted on the
luminal side of the endothelial cell (including redox and oxidative stress with ROS) result in the adaptive changes in which we
are familiar: Remodeling of the arterial vessel wall: From Atheroma to Atherosclerosis, to Atheroscleropathy: A MALIGNANT
TRANSFORMATION.Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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"I believe the chief cause of premature development of
arteriosclerosis in diabetes, save for advancing age, is
due to an excess of fat, an excess of fat in the body,
obesity, an excess of fat in the diet, and an excess of fat
in the blood. With an excess of fat diabetes begins and
from an excess of fat diabetics die, formerly of coma, re-
cently of arteriosclerosis."[5] Refer to A-FLIGHT toxici-
ties sections (F), (L), (T).
This master clinician of diabetes was one of the first phy-
sicians to make the association regarding the double jeop-
ardy of type 2 diabetes mellitus and atheroscleropathy
with its associated morbidity and mortality in cardiovas-
cular disease.
Recognition of the prophetic view of Joslin has now been
fulfilled in the 2001 National Cholesterol Education Pro-
gram Adult Treatment Panel III guidelines. Diabetes (both
T1DM and T2DM) is now considered a coronary risk
equivalent and the metabolic syndrome is included in the
multiple risks factors for the development of atheroscle-
ropathy. [6]
For today's atherosclerologists the history of atherosclerosis
is rich and the theories are legion. Even today, knowledge
in this field of study is expanding exponentially. In this re-
view, we will try to remain focused on intimal redox stress
and how this interacts with the manifold toxicities of IR,
MS, PD, and T2DM to result in a unique accelerated
atherosclerosis which shall be called atheroscleropathy.
Redox homeostasis, redox stress, and oxidative stress
Cellular respiration (the transference of electrons between
oxygen species) allows each of us to survive on this planet
not only at the cellular level but also as an organism.
Homeostasis is a key element to all healthy physiologic
functions throughout the body and when there is loss of
homeostasis, there is usually disease.
Redox homeostasis describes the normal physiologic
process of reduction and oxidation in order to re-pair un-
stable, damaging, reduced, reactive oxygen species (ROS)
which will include the following oxygen free radicals (O2'
– superoxide, H2O2 – hydrogen peroxide, -OH' hydroxyl
radical, and singlet oxygen) and organic analogues which
include reactive nitrogen species (RNS) primarily perox-
ynitrite ONOO'.
This homeostatic balance between ROS and antioxidant
capacity is in contrast to redox stress (redox imbalance)
which implies a loss of this unique homeostasis resulting
in an excess production of ROS (tables 1 and 2) either
through the process of reduction or oxidation.
Oxidative Stress implies a loss of redox homeostasis (im-
balance) with an excess of ROS by the singular process of
oxidation. Both redox and oxidative stress may be associ-
ated with an impairment of antioxidant defensive capacity
as well as an overproduction of ROS.
It has been known for some time that ROS are detrimental
and toxic to cells and tissues as a result of injury to lipids,
nucleic acids, and proteins: (A). Lipid peroxidation of
membranes (loss of membrane function and increased
permeability) and generation of lipid autoperoxidation
reactions. (B). DNA damage leading to mutation and
death. (C). Cross linking or vulcanization of sulfhydryl
rich proteins (leading to stiff aged proteins specifically
collagen of the extracellular matrix). [7]
The evolutionary process of redox homeostasis allows hu-
mans to survive in an atmosphere of high oxygen content.
In addition our bodies have become "hard wired" to uti
Table 1: Courtesy [9] origins of reactive oxygen species (ROS) which produce redox stress
I Excess O2 (oxygen therapy)
II Absorption of radiant energy (ultraviolet light) or ionizing radiation (radiotherapy)
III Exposure to toxins: carbon tetrachloride, dioxin, alloxan and streptozotocin to name just a few
IV Reduction-oxidation (redox) reactions during normal physiologic processes (cellular respiration)
A. Respiratory chain enzymes and oxygen
B. Xanthine oxidase
C. Cytochrome P450 monooxygenase activity
D. NAD(P)H / NADH oxidase
E. Fenton reaction: Fe++ + H2O2  Fe+++ + OH + OH-
F. Haber-Weiss Reaction H2O2 + O2
-  -OH- + O2 +OH-
V Ischemia – Ischemia reperfusion injury
VI Inflammatory processes. Acute and chronic
VII Once free ROS radicals form, they can react with membrane lipids, proteins and nucleic acid to initiate auto-catalytic 
reactions (ROS beget ROS) [9]Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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Table 2: Courtesy [9] Origins of reactive oxygen species (ROS) and cellular location
Nicotinamide adenine dinucleotide reduced (NADH)
NADH Oxidase NADH / NAD+ (mitochondrion, cytosol)
NADH + 2O2  NAD+ + H+ + 2O2
- (Super Oxide)
Nicotinamide adenine dinucleotide phosphate reduced (NAD(P)H)
NAD(P)H Oxidase NAD(P)H / NAD(P)+ (membrane)
NAD(P)H + 2O2  NAD(P)+ + H+ + 2O2
- (Super Oxide)
Super oxide dismutase (SOD):
MnSOD = Mitochondrial SOD
CuZnSOD = Intracellular (cytosolic) SOD
EcSOD = Extracellular SOD
O2
- + SOD  H2O2 (hydrogen peroxide)
Fenton Reaction: H2O2 + Fe++  -OH' (the hydroxyl radical) * + Fe+++ + OH-
Haber-Weiss Reaction: H2O2 + O2
-  -OH- (the hydroxyl radical) + O2 +OH-
Peroxynitrite: origins of reactive nitrogen species (RNS)
O2
- is consumed. Nitric oxide (NO) is also consumed in this process with the creation of reactive nitrogen species (RNS).
O2
- +NO  ONOO- (peroxynitrite) + tyrosine  nitrotyrosine
O2
- +NO  ONOO- (peroxynitrite) + arginine  nitroarginine
Nitroarginine competes for arginine in the formation of eNO.
Nitrotyrosine reflects redox stress and leaves an indelible measurable footprint.
NO: the good; O2
-: the bad; ONOO-: the ugly [122,9]
Table 3: Courtesy [8,9] The manifold toxicities of insulin resistance, metabolic syndrome and T2DM
A-FLIGHT toxicities
A Amylin (hyperamylinemia)/amyloid toxicity ROS
Ang II (also induces PKC) ROS
AGEs/AFEs (advanced glycosylation/fructosylation endproducts) ROS
Antioxidant reserve compromised ROS
Absence of antioxidant network ROS
Ageing ROS
Angiogenesis (induced redox stress) Arteriogenesis (impaired PAI-1) ROS
Atherosclerosis – Atheroscleropathy. [ROS beget ROS] ROS
F Free fatty acid toxicity ROS
L Lipotoxicity ROS
I Insulin toxicity (hyperinsulinemia-hyperproinsulinemia) (endogenous) ROS
Inflammation toxicity ROS
G Glucotoxicity (compounds peripheral insulin resistance) reductive 
stress Sorbitol / polyol pathway
ROS plus
Pseudohypoxia (NADH/NAD increased) PKC
H Hypertension toxicity ROS
t homocysteine toxicity ROS
T Triglyceride toxicity ROS
See reference [8,9]Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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lize the mechanism of redox stress injury to fend off in-
vading infectious organisms and survive our environ-
ment.
Paradoxically, (when there is loss of homeostasis resulting
in redox or oxidative stress) this protective mechanism
turns on our own cells; tissues and causes damage, espe-
cially the intima in the atheroscleropathy associated with
MS, IR, PD, and overt T2DM. This constellation of MS, IR,
PD, and T2DM is associated with an elevated tension of
redox stress within the intima (also the islet in MS, IR, PD,
and T2DM) due to multiple toxicities. (table 3) Each of
these A-FLIGHT toxicities result in the formation of dam-
aging ROS. [8,9]
Not only are ROS involved in the development of type 1
diabetes mellitus (T1DM) and T2DM but also play an im-
portant role in the long-term development of the associat-
ed complications: The multiple diabetic-opathies (A –
DINNER: atheroscleropathy, angiogenesis (accelerated)
and arteriogenesis (impaired), diabetic cardiomyopathy
and dermopathy, intimopathy, nephropathy, neuropa-
thy, enteropathy, retinopathy (table 4). This review will
focus primarily on the association of redox stress in the in-
tima and how it interacts with MS, IR, PD, and T2DM.
Metabolic syndrome and insulin resistance
IR describes the condition whereby there is a resistance to
insulin mediated glucose uptake by cells and is central to
the clustering of multiple metabolic abnormalities and
clinical syndromes (figure 3). The clustering phenome-
non was first described by Kylin in 1923 when he de-
scribed the clustering of three clinical syndromes:
hypertension, hyperglycemia, and hyperuricemia. [10]
In 1936 Himsworth [11] noted that a large number of di-
abetic patients were insulin insensitive and suggested that
diabetics be divided into groups that were insulin sensi-
tive and insulin insensitive.
Yalow and colleagues in 1965 [12] were first to discover
an insulin assay and reported that IR was a condition in
which insulin does not produce the same glucose lower-
ing effects seen in insulin-sensitive individuals.
These concepts were rejuvenated and immortalized by
Reaven in 1988 given as the Banting lecture.[13] The clus-
tering phenomenon has gone by many names since Dr.
Reaven first described the metabolic and clinical associa-
tions of the many names of Syndrome X. (table 5)
By 1999, the World Health Organization had chosen a
unifying definition for this syndrome of many names and
elected to use the term metabolic syndrome rather than
the insulin resistance syndrome because they felt it was
not well established that insulin resistance was the cause
of all components of the syndrome.[14]
Additionally, there are at least a dozen factors that link
clinical suspicions to the metabolic syndrome. (table 6)
Factors and findings in this syndrome occur together all to
frequently to be considered a coincidence and there are
common underlying factors that may explain this coexist-
ence. Namely, the well documented hyperinsulinemia
story and the more recent hyperamylinemia and amylin
derived islet amyloid story. [8,9]
MS affects approximately 47 million or greater Americans.
[15] Of these 47 million, only 20% will develop T2DM
and the remaining 80% will be able to compensate (at
least for a period of time) through the process of beta cell
Table 4: Multiple diabetic-OPATHIES.
A-DINNER
A ATHEROSCLEROPATHY. ANGIOGENESIS (induced). ARTERIOGENESIS (impaired).
D DERMOPATHY: Diabetic Scleroderma – Stiff skin, vulcanization of collagen (cross-linking). Necrobiosis Lipoidica 
Diabeticorum. Brown sunken atrophic scars anterior shin of legs (impaired scar formation associated with increased 
levels of PAI-I and impaired injury remodeling).
I INTIMOPATHY. INTIMAL REDOX STRESS. Macro vascular plus micro vascular vasa vasorum angiogenesis 
with intraplaque hemorrhage  Coronary Events.
N NEPHROPATHY. Microvascular.
NN E U R O P A T H Y .  Microvascular. Overriding sympathetic stimulation pro vasoconstrictive.
EE N T E R O P A T H Y .  Delayed gastric emptying.
R RETINOPATHY. Microvascular.
Observations from Table 4: Intimopathy and atheroscleropathy are very similar. Similar shared glucotoxicity in T1DM and T2DM. Dissimilar toxici-
ties in that the toxicities of MS, IR, PD and the role of the aging process predate the development of overt T2DM. See reference [8,9]Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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expansion, hypertrophy, and hyperplasia (utilizing the
replicative pool of periductal cells). [16,17]
The resulting hyperinsulinemia, hyperamylinemia (37.6
million = 80% of 47 million) does not come without a
price to pay as this compensatory mechanism places these
patients at risk for hypertension, atheroscleropathy, and
subsequent coronary artery disease. [18,19] (figure 3) See
section (A). Ang II, (A). Amylin toxicity, and (I). Insulin
toxicity.
The manifold – A-FLIGHT toxicities
(A). Angiotensin II toxicity
Angiotensin II (Ang II) is associated with hypertension,
MS, IR, PD, and T2DM both systemically and at the local
tissue level. Currently, there is evidence that a local tissue
renin angiotensin aldosterone system (RAAS) is operative
within the intima and islet as angiotensin type one (AT-1)
receptors have been identified as being present on smooth
muscle cells, endothelial cells, and the beta cells within
the intima and islet [20,21] Insulin is known to upregu-
late the AT-1 receptor [22] and there exists cross talk be-
tween the insulin and the Ang II signaling systems [23] In
1995, Copper et al. were able to demonstrate that amylin
activates the RAAS with elevations in renin and aldoster-
one in humans [24] and, in 2001, Ikeda et al. were able to
demonstrate that insulin, proinsulin and amylin infu-
sions resulted in significant increases in renin release and
that proinsulin and amylin enhanced this insulin-stimu-
lated renin release in the perfused rat kidney [25].
Taken together, these data support the strong influence of
a local RAAS mechanism operating within the intima and
islet for the local production of excess Ang II. The islet is
Figure 3
The cluster of multiple abnormalities are associated with the metabolic syndrome and insulin resistance is central to the devel-
opment of ATHEROSCLEROPATHY, cardiovascular disease, and events in the patient with MS, IR, PD, and overt T2DM.
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quite vascular with an abundant supply of intra islet cap-
illaries and endothelial cells and the intima is lined by a
continuous monocellular layer of endothelial cells (addi-
tionally, the arterial vessel wall becomes highly vascular
through the process of plaque angiogenesis as the vulner-
able plaque evolves during the process of atheroscleropa-
thy).
This allows the vascular NAD(P)H oxidase enzyme to
come into play. Ang II is one of the most potent endog-
enous stimuli for the generation of superoxide O2
- via the
activation of vascular NAD(P)H oxidase. [26,27]
The interruption of this mechanism by the angiotensin
converting enzyme inhibitor (ACEi) ramipril in the Heart
Outcomes Prevention Evaluation (HOPE) study may help
to explain the 32% risk reduction for developing T2DM as
well as the dramatic reduction in cardiovascular events.
[28]
A special reference to Griendling and Harrison seems ap-
propriate: "Out, damned DOT! Out I say" (where the
damned DOT represents the unpaired dots on Lewis dia-
grams). [29] One of the best ways to prevent these dots
from forming is to prevent excess substrates (table 3)
which cause the multiple toxicities and the multiplicative
effect of the A-FLIGHT toxicities associated with MS, IR,
PD, and T2DM.
In MS, IR, PD, and T2DM the intima and islet milieu will
be laden with the necessary substrates (hyperinsulinemia,
hyperproinsulinemia and hyperamylinemia) to activate
the damaging cascading mechanism of Ang II, NAD(P)H
oxidase, superoxide (O2
-) and peroxynitrite (ONOO-)
production while consuming the natural endogenously
produced antioxidant nitric oxide (NO) within the vul-
nerable intima and islet.
(A). Advanced glycosylation endproducts: AGE
Advanced glycosylation endproducts (AGEs) are formed
as a result of the non-enzymatic damaging protein glyca-
tion due to an excess of glucose (hyperglycemia) present
in both T1DM, PD, and T2DM. AGEs are initially formed
through the process of a glucose nucleophilic addition re-
action with proteins forming a Schiff base followed by the
formation of an Amadori compound which undergoes
further reactions, rearrangements, dehydrations and
cleavage resulting in brown insoluble, cross linked com-
plexes called AGEs. This process is thought to liberate
H2O2 through two pathways: the first is the 1,2-enoliza-
tion pathway which leads to 3-deoxyglucosone forming
H2O2 and glucosone; the second pathway is the 2,3-eno-
lization pathway leading to 1-deoxyglucosone and puta-
tive 1,4-deoxyglucosone. Under oxidative conditions, the
2,3-enediol is thought to generate H2O2 and car-
boxymethyllysine. 3-deoxyglucosones are known to be
both highly reactive intermediates in non-enzymatic glyc-
osylation and also potent cross-linkers which are respon-
sible for the polymerization of proteins to AGEs. These
highly cross-linked proteins, especially collagen, cause a
stiffening within the vessel which results in decreased
compliance of the arterial vessel wall and may well play
an important role in the development of diabetic diastolic
dysfunction, diabetic cardiomyopathy, and the diastolic
dysfunction of the arterial vessel wall. Furthermore, there
are advanced fructosylation endproducts (AFEs), which
actually have a greater affinity binding to proteins than
glucose and follow a similar pattern in the production of
the ROS. [30–33] An excellent in depth review of AGE can
be found in an article by Aronson and Rayfield where they
discuss how hyperglycemia promotes atherosclerosis [34].
The multiligand immunoglobulin superfamily cell surface
receptor: the receptor for advanced glycation endproducts
(RAGE) is up-regulated by the presence of AGE and results
in the signal transduction of nuclear factor kappa B
(NFkappa B) which then results in a chronically active in-
flammatory state and links this section to section (I). In-
flammation Toxicity and atheroscleropathy. [35,36]
(A). Antioxidant enzymes
Antioxidant reserve compromised
In addition to the excess generation of the ROS seen in di-
abetes, there exists an impaired generation of endogenous
antioxidants. Superoxide dismutase (SOD), [37] glutath-
ione reduced (GSH), [38] and ascorbic acid (Vitamin C)
[39] are all decreased and associated with atheroscleropa-
thy in diabetes. Moreover, there is evidence of the dimin-
ished capacity of other antioxidants such as uric acid and
vitamin E with a reduced activity of catalase and glutath-
ione peroxidase (GPx). (Table 6) [40] The exact mecha-
nisms of impairment are still not completely understood
but two explanations exist. Protein glycation may be a
Table 5: Courtesy [8,9] The myriad names of the metabolic 
syndrome
I. The insulin resistance syndrome
II. Syndrome X
III. Reaven syndrome
IV. Metabolic syndrome (preferred term by 
WHO)
V. Metabolic syndrome X
VI. Multiple metabolic syndrome
VII. Plurimetabolic syndrome
VIII. Dysmetabolic syndrome
IX. Cardiovascular dysmetabolic syndrome
X. Cardiometabolic syndrome
XI. The "H" phenomenon
XII. The "Deadly quartet"Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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mechanism that damages the protein within the primary
antioxidant enzymes, and the antioxidant enzymes which
are co-dependent on one another, may be dysfunctional if
one or the other is being consumed by an overactive de-
mand such as compromised GSH function due to the de-
pletion of NADH in the polyol pathway.
It seems quite logical that both mechanisms may be in
play at one time or another in the diminished antioxidant
defense mechanisms. Another example is glutathione di-
sulfide (GSSG) which is reduced to GSH at the expense of
NAD(P)H. [41]
Absence of network antioxidant enzymes
eNOS
The absence of network antioxidant enzymes could play
an additional role. A good example of this condition
would be the endothelial nitric oxide synthase (eNOS) -/-
knockout mouse model by Duplain and Scherrer.
They were able to demonstrate that insulin resistance, hy-
perlipidemia, and hypertension were present in mice lack-
ing the specific isoform eNOS. This implicates eNOS not
only in the endothelial cell (important in the regulation of
arterial pressure) but also in the loss of its expression in
skeletal muscle which impairs insulin stimulated glucose
uptake, and that its loss (both at the endothelial and skel-
etal muscle sites) impairs lipid homeostasis and creates
insulin resistance. [42] This represents the loss of the nat-
urally occurring free oxygen radical scavenging antioxi-
dant effect of endothelial nitric oxide (eNO) (Table 7).
Does this apply to humans?
There is evidence of a gene polymorphism in humans and
recently Miyamoto et al.[43] were able to demonstrate
that a gene polymorphism, Glu298Asp in exon 7 of the
eNOS gene, was associated with coronary spastic angina
and myocardial infarction and found further evidence for
this gene polymorphism in the statically significant asso-
ciation with the development of essential hypertension in
two separate Japanese populations. There could be other
gene polymorphisms in other populations as well as in
other antioxidant genes that relate to insulin resistance,
metabolic syndrome, and hypertension. As the human ge-
nome evolves, we are certain to find other alterations in
various populations throughout the world.
Asymmetrical dimethylarginine (ADMA) has recently
been shown to be associated with endothelial dysfunction
and increased risk of cardiovascular disease. Stuhlinger,
Reaven, Tsao, and colleagues were able to demonstrate a
positive correlation with impaired insulin-mediated glu-
cose disposal and elevated levels of ADMA. Plasma ADMA
concentrations increased in insulin-resistant subjects in-
dependent of hypertension. Increases in plasma ADMA
concentrations may contribute to the endothelial dys-
function observed in insulin-resistant patients.
Elevated levels of ADMA have been observed in IR, hyper-
tension, hyperlipidemia, hyperglycemia, hyperhomo-
cysteinemia, and renal failure. ADMA is formed by
protein arginine N-methyltransferases and LDL-C both
native and oxidized up regulates PRMT's increasing AD-
MA. [44,45]
Under physiologic homeostatic conditions, eNOS is the
endothelial constitutive (rate limiting) enzyme responsi-
ble for the conversion of L-arginine to NO and L-citrul-
line. It requires a cofactor tetrahydrobiopterin (BH4).
There is a paradoxical uncoupling of the eNOS enzyme
that allows this above reaction to be capable of producing
superoxide (O2') if there is insufficient BH4, L-arginine,
or if there is direct interference with and/or defect in the
eNOS enzyme. Uncoupling of eNOS enzyme results in the
production of damaging O2' adding to the oxidative stress
within the arterial vessel wall.
Table 6: Courtesy [53] Factors that link clinical suspicions to insulin resistance, metabolic syndrome, and a proclivity to develop T2DM.
I. Strong family history of diabetes mellitus.
II. High risk ethnic background (Aboriginal, Asian, Pacific Islander, Hispanic, African American, Native American Indian).
III. Obesity (visceral, omental). Phenotypic changes of abdominal obesity: waist/hip ratio equal or greter than 1 in males and 
equal or greter than 0.8 in females.
IV. Gestational diabetes.
V. Macrosomia.
VI. Multiparity.
VII. Polycystic ovary syndrome (PCOS).
VIII Impaired glucose tolerance. Two-hour postprandial blood sugar ranging from 140 to 199 mg/dL after 75 gram OGTT
IX. Impaired fasting glucose : 110–125 mg/dL.
X. Aging.
XI. Hypertension.
XII. Dyslipidemia. The lipid triad (increased VLDL, triglycerides, small dense LDL. Decreased HDL).Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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Causative factors for eNOS uncoupling are as follows: In-
creased O2' and ONOO', elevations in glucose and both
native LDL-C and oxidatively modified, mmLDL-C, hy-
perhomocysteinemia see section (H), decreased or im-
paired Cofactor BH4, decreased L-arginine, increased
ADMA, and C reactive protein. In time there will in all
probability be other causative factors that disable the
eNOS enzyme resulting in increased oxidative stress. Ad-
ditionally, diabetic endothelium has been shown to be a
net producer of superoxide O2' instead of nitric oxide NO
resulting in a decreased ratio of NO / ROS [46–51] (figure
4)
The ROS stemming from the A-FLIGHT toxicities addi-
tionally play a role in the competitive inhibition of eNOS.
Redox stress results in the production of nitroarginine as
well as nitrotyrosine. Nitroarginine then competes with L-
arginine as a substrate for eNOS to generate NO. Stepp
and colleagues were able to demonstrate a 4 fold increase
in O2' and an 8 fold increase in O2' when endothelial
Figure 4
The various subunits of the plasma membrane bound reaction responsible for the production of eNOS derived nitric oxide
(NO). This reaction can uncouple and be a net producer of [O2']. In diabetes there are several reasons for uncoupling.
Decreased or dysfunctional eNOS enzyme, substrate L-arginine, deficient or dysfunctional cofactor BH4. Increased ROS, RNS,
glucose, native LDL-C and oxidized mmLDL-C, ADMA, Hcy, and CRP. Each of these factors can contribute to making the
endothelium of the patient with MS, IR, PD and overt T2DM a net producer of [O2']. The above dysfunctional endothelium
with a decreased ratio of NO / ROS. RNS can further contribute to the overall increase in intimal redox stress and atheroscle-
ropathy.
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Due to uncoupling of eNOS enzyme.
Couples with NAD(P)H
L-arginine.Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
Page 11 of 27
(page number not for citation purposes)
cells were exposed to native LDL-C and mmLDL-C respec-
tively. This uncoupling of eNOS plays an important role
in endothelial cell dysfunction and increased oxidative
stress. [47] Hyperglycemia and peroxynitrite (ONOO')
also induce eNOS uncoupling with increases in O2' pro-
duction. [48] Just published, Verma S and colleagues re-
ported that CRP caused a marked down regulation of
eNOS mRNA and protein expression with subsequent
lower eNO production. The authors point out that CRP
may not just be a marker of atherosclerosis and increased
risk of acute coronary events, but may also be a mediator
of this disease process. Strategies designed to lower CRP
may reduce cardiovascular risk by directly improving bio-
availability of NO and endothelial function. [49] See sec-
tion (I). Inflammation.
There are undoubtedly many more scenarios in which
eNOS can be impaired with resulting decreased NO but at
this point in time it is certainly interesting to see a tight
connection of impaired eNOS and the MS, IR, PD, and
T2DM. Additionally, the synergistic importance regarding
elevations of both glucose and native LDL-C or mmLDL
which result in elevations of the detrimental superoxide
(O2') can uncouple the eNOS enzyme leading to even fur-
ther increases in O2'. The importance of treating LDL-C,
HbA1c, and hypertension to goal are therefore paramount
in reducing the oxidative damage and endothelial cell dys-
function. (table 9) (figure 6) These examples only
strengthen the statement that ROS beget ROS.
The synergism and the vicious cycle of redox and oxidative
stress to the arterial vessel wall from ROS produced by vas-
cular cells, especially the endothelium, as a result of the A-
FLIGHT toxicities necessitates an aggressive global ap-
proach. Wong T.Y. and colleagues for the Atherosclerosis
Risk In Communities (ARIC) Investigators were able to
show that retinal arteriolar narrowing was independently
associated with the risk of developing future diabetes. This
supports a microvascular role in the development of clin-
ical diabetes and provides clinical evidence to support a
hypothesis that eNOS and endothelial dysfunction may
be implicated in the pathogenesis of diabetes. This new
clinical information, of arteriolar narrowing preceding the
clinical onset of diabetes and implicating endothelial cell
dysfunction (including an eNOS defect) could play a ma-
jor important role in the development of this polygenic –
multifactorial disease of MS, IR, PD, overt T2DM and
atheroscleropathy. [52]
This leads to an interesting Hypothesis:
                        Could it be that T2DM is really a cardiovascular
disease (evolving around a primary eNOS enzyme dys-
function or defect with an effect on MS and IR) with a late
manifestation of glucose elevation i.e. PD and overt
T2DM? This would certainly tie the natural history of
T2DM and atheroscleropathy together                        [53].                     
Other antioxidant enzymes
If any one of the antioxidant enzymes (table 7) is missing
or impaired or any combination of them are impaired,
then we would expect to see a similar event as in the
knockout mouse model. It would not have to be a com-
plete knockout of the enzyme, as discussed above, as var-
ious gene polymorphisms could exist which could result
in a decreased antioxidant reserve.
(A). Ageing
Ageing has been shown to be associated with an increased
risk of developing T2DM and atheroscleropathy. Ageing
allows the multiplicative effects of the A-FLIGHT toxicities
to become manifest. Advanced ageing leads to impaired
endothelial nitric oxide synthesis and also enhanced en-
dothelial apoptosis.
In addition, aged cells have a significantly enhanced con-
centration (more than 3 fold) of oxidized low density li-
poprotein, TNFalpha and caspase-3 activity as compared
to young cells. The decrease in eNO associated with aged
cells creates a deficiency of the naturally occurring antioxi-
dant eNO. [54]
Similarly, excess redox stress is felt to contribute to ageing.
Information on the relationship of redox stress and ageing
and inflammation (see section "(I). Inflammation Toxici-
ty") is rapidly increasing and gaining wider recognition.
[55,56]
(A). Amylin toxicity
Amylin, also termed islet amyloid polypeptide (IAPP) is a
37 amino acid polypeptide co-synthesized, co-packaged,
and co-secreted by the islet beta cell with insulin. It may
be considered insulin's a fraternal twin.
Amylin parallels insulin synthesis, secretion, and excre-
tion so that whenever you have hyperinsulinemia you
have hyperamylinemia and, in the same way, when insu-
lin levels decline amylin levels decline.
Amylin stimulates lipolysis in vivo and may be a possible
mediator of induced insulin resistance. Ye et al., were able
to demonstrate that amylin infusion (5 nmol/h for 4 h)
conscious rats that fasted for 5–7 hours resulted in an ele-
vation of insulin, lactate and glucose (P < 0.05 vs. con-
trol).
Despite the rise in insulin, plasma non-esterified fatty acid
and glycerol were also elevated (P < 0.001). Although the
plasma triglyceride content was unaltered, the triglyceride
content in the liver was increased by 28% (P < 0.001) withCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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a similar tendency in muscle (18%, P = 0.1). These effects
were blocked by the rat amylin antagonist amylin-(8–37)
and also by the anti-lipolytic agent acipimox. The authors
concluded that amylin could exert a lipolytic-like action
in vivo. [57]
This elevation in amylin would correspond to the insulin
resistant state with associated elevation in amylin in hu-
mans. These data indicate that amylin may play a role by
elevating free fatty acids which would aggravate or induce
the underlying insulin resistance and provide a mecha-
nism for increasing the free fatty acid substrate for in-
creased redox stress, cytotoxicity and intimal remodeling
associated with atheroscleropathy.
There are amylin binding sites within the renal cortex and
amylin activates the RAAS with elevations in renin and al-
dosterone [24]
Figure 5
Vulnerable plaques are proinflammatory, profibrotic, prothrombotic, proangiogenic, lipid ladened and recently found to be
acidic. The activated endothelium is associated with endothelial dysfunction due to eNOS dysfunction and eNOS uncoupling
with resultant overproduction of superoxide [O2']. Diabetes is associated with a dysfunctional endothelium not only at sites of
vulnerable plaque but have been shown to be a systemic net producer of [O2']. The inflammatory cells and intimal remodeling
are depicted in this image as well as an intraplaque hemorrhage (IPH) from the angiogenic vasavasorum vessels originating from
the adventitia of this lipid ladened vulnerable plaque. Redox stress and ROS play a prominent role within the intima. The profi-
brotic arm of the unstable VP is responsible for the positive outward and negative inward remodeling.
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These findings suggest that glucotoxicity resulting in AGE
formation both promotes and accelerates redox stress.
[58]
Janson et al. have found that intermediate sized toxic amy-
loid particles (ISTAPs) have been found to be cytotoxic to
beta cells inducing apoptosis by membrane disruption.
[59]
(A). Angiogenesis (accelerated): Arteriogenesis (impaired): Vasculari-
zation Paradox In T2DM
The process of Angiogenesis starts with capillaries and ends with 
more capillaries
As the atheroma matures there is an associated intense
plaque angiogenesis arising primarily from the adventitial
vasa vasorum (atherosclerotic intimopathy). These vessels
invade the arterial vessel wall in a malignant like fashion.
This plaque vascularization (angiogenesis) corresponds to
the presence of the inflammatory infiltrate at the shoulder
of these lesions, the development of the large lipid core,
the thin fibrous cap, and the decrease in SMCs within the
fibrous cap, to form, what we now term the vulnerable
plaque. [1–4]
Extensions of the vasa vasorum (the vessels within a ves-
sel) act as a custom delivery system within the vessel walls'
vulnerable shoulder region supplying: 1. substrates of the
RAAS; 2. substrates of native LDL-C; 3. the second wave of
inflammatory cells; 4. inflammatory mediators (various
cytokines and growth factors); and 5. provide an addition-
Figure 6
Venn diagrams revealing the multiple intersects of this quartet of MS, IR, PD, and overt T2DM. The morbid – mortal intersec-
tion of T2DM and Accelerated Atherosclerosis (ATHEROSCLEROPATHY) are a result of the interweaving threads that weave
this complicated mosaic fabric.
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al conduit and source of redox stress at the endothelial cell
– extracellular matrix interface within these vulnerable
plaques.
This process is accelerated in the MS, IR, PD, and T2DM as
well as the T1DM patient. Vasa vasorum derived fragile
capillary-like vessels are prone to rupture and create intra
plaque hemorrhages (IPH) which destabilize the plaque
and promote the possibility of being prone to rupture
with ensuing cardiovascular events. The pseudohypoxia
(increased ratio of NADH/NAD+ discussed by William-
son and Kilo see section (G) glucotoxicity.) in the polyol-
sorbitol pathway as well as the true hypoxia induced by
the increasing intima media thickness may act to induce
the nuclear hypoxia inducible factor (hif-1) within the
smooth muscle and endothelial cells which result in the
increased expression of vascular endothelial growth factor
VEGF which is so central and vital to the angiogenic proc-
ess. This diabetic atherosclerotic intimopathy (plaque an-
giogenesis) would be akin to the diabetic retinopathy.
[3,60–62]
The process of arteriogenesis starts with small arterioles and ends 
with larger arterioles
In contrast the vascularization process of arteriogenesis is
impaired. Even though patients with diabetes (both
T1DM and T2DM) have a much higher number of athero-
sclerotic diseased arteries, mean coronary collateral ves-
sels (CCV) are significantly decreased. [63]
Elevations in plasminogen activator inhibitor-1 (PAI-1)
are present in the MS, IR, PD, and T2DM patient. Remod-
eling collateralization (arteriogenesis) is stimulated by the
tissue and urokinase plasminogen activators (tPA and
uPA). PAI-1 elevations decrease the conversion of plas-
minogen to plasmin because it inhibits tPA and uPA. As
plasmin is impaired there is a reduction of the conversion
of inactive or pro-MMP-1 to active MMP-1 with inhibition
of ECM turnover with resultant impaired CCV formation.
This paradox in diabetes vascularization contributes great-
ly to the known poor outcomes associated with cardiovas-
cular events in the diabetic. [3]
(A). Atherosclerosis and atheroscleropathy
Once atherosclerosis and atheroscleropathy has been ini-
tiated and sustained, this process is self – perpetuating
Table 7: Courtesy [9] Antioxidants: catalytic/enzymatic inactivation of free radicals
Enzymatic antioxidants
SUPER OXIDE DISMUTASE (SOD) – Location: mitochondrion
[O2
- + SOD  H2O2 + O2]
ecSOD (extracellular)
MnSOD (mitochondrial)
CuZnSOD (intracellular)
CATALASE – Location: peroxisome
[2H2O2 + catalase  2 H2O + O2]
GLUTATHIONE PEROXIDASE – Location: mitochondrion/cytosol
(Glutamyl-cysteinyl-glycine tripeptide) glutathione reduced -SH to the oxidized disulfide GSSG.
(Glutathione peroxidase) [GSH + 2H2O2  GSSG + H2O + O2]
(Glutathione reductase) [GSSG  GSH] at the expense of [NADH  NAD+] and/or [NAD(P)H  NAD(P)+]
*NOS (nitric oxide synthase). – Location: membrane
Isoforms:
(e) NOS (endothelial): good (importance of eNOS uncoupling) LDL native and oxidized.
(n)NOS (neuronal): good
(i)NOS (inducible-inflammatory): good in host defense. BAD in chronic inflammation.
O2
- and nitric oxide (NO) are consumed in this process with the creation of reactive nitrogen species (RNS).
O2
- + NO  ONOO- (peroxynitrite) + tyrosine  nitrotyrosine. (also causes eNOS uncoupling)
Nitrotyrosine reflects redox stress and leaves a measurable footprint.
NO: the good; O2
-: the bad; ONOO-: the ugly [122]
eNOS uncoupling causes the generation of O2' instead of NO induced by LDL-C, Glucose, O2', and ONOO'.
Nonenzymatic antioxidants
URIC ACID
VITAMIN A
VITAMIN C
VITAMIN E
THIOLS
APOPROTEINS: Ceruloplasmin and transferrin. Bind copper and iron in forms which cannot participate in the Fenton reaction. [9]Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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(self sustaining) and the vicious cycle of ROS begetting
ROS comes into play with all of its inherent complica-
tions. It's as if the multiple A-FLIGHT toxicities polymer-
ize with redox stress and its associated ROS acting as an
accelerant. The associated ischemic cardiomyopathy and
the distinct diabetic cardiomyopathy are not within the
scope of this review.
(F). Free fatty acids
Free fatty acid (FFA) elevation is known to be associated
with IR, MS, PD, and T2DM. The metabolically active
form of FFAs are cytosolic long-chain acyl-CoA esters
(LCACoA) and are responsible for cytosolic neutral trig-
lyceride deposition in adipose and non-adipose tissues.
In 2001, McGarry gave an excellent presentation at the
American Diabetes Association meeting (ADA 2001 Ban-
ting Lecture), discussing in detail how toxic FFA and LCA-
CoA may be important in the development of insulin
resistance, progressive beta cell dysfunction and death as-
sociated with T2DM. [64]
Central obesity is associated with increased cytosolic neu-
tral fat triglyceride stores in adipose and non-adipose tis-
sues such as muscle (skeletal and cardiac), the liver,
pancreatic beta cells and, possibly, endothelial cells.
[64,65]
Intra-myocellular lipid was found to be more highly cor-
related with insulin resistance than any other commonly
measured indices such as body mass index, waist-to-hip
ratio or total body fat. Low insulin sensitivity was accom-
panied by a marked increase in intra-myocellular lipid.
Bakker et al.[65] proposed that the chronic low-grade pro-
duction of ROS produced by respiring mitochondria is en-
hanced by excessive cytosolic triglyceride stores and
LCACoA esters in non-adipose tissue.
They proposed that LCACoA esters exert an inhibitory ef-
fect on the adenosine nucleotide translocator with a re-
sultant decrease in the ADP available. This decrease in
ADP slows the flow of electrons along the electron transfer
chain and increases the possibility of having single un-
paired electrons to create the superoxide anion (O2
-) in-
creasing oxidative mitochondrial stress, thus resulting in a
dysfunctional cell. Moreover, they suggest that these phe-
nomena not only accelerate the atherosclerotic process
but also induce endothelial dysfunction and microalbu-
minuria prior to the development of T2DM and possibly
beta cell dysfunction and failure. [65]
It is difficult to completely separate FFA toxicity from the
sections which follow on lipoprotein toxicity and triglyc-
eride toxicity as there is a dynamic relationship between
these three in the A-FLIGHT toxicities. In fact, FFAs are
transported by the protein fraction, albumin, and lipases
are constantly removing the long chain fatty acids from
the glycerol backbone of triglycerides at the interface of
the capillary endothelial cells creating free fatty acids
which can freely move into cells throughout the body. In-
tracellularly, the FFAs are then added to the glycerol back-
bone in order to form cytosolic triglycerides stored as
neutral fat, or are oxidized for fuel and energy generating
ATP. If mitochondrial beta oxidation is over utilized or
dysfunctional, the excess may then undergo the toxic non-
beta non-mitochondrial pathway generating toxic FFAs or
ceramide (see section "(L). Lipotoxicity – Specific").
L). Lipotoxicity – generalized
Lipotoxicity promotes oxidative stress and is associated
with MS, IR, PD, and T2DM. There is an associated defect
of lipoprotein metabolism frequently referred to as the
"lipid triad". Elevated VLDL or triglycerides, atherogenic
small dense LDL, and decreased HDL comprise this triad
which is associated with atheroscleropathy and coronary
heart disease as well as increased redox stress. [66–68]
The increased VLDL, triglycerides, atherogenic small
dense LDL cholesterol and the diminished amount of the
anti-atherogenic, antioxidant anti-inflammatory high
density lipoprotein cholesterol would reduce the natural
antioxidant reserve. This combination supports an in-
crease in redox stress in addition to the previously dis-
cussed FFA toxicity. This also tends to support the
oxidation, glycation and glycoxidation of existing lipo-
proteins (modification) which results in increased ROS
and redox stress.
Lipoproteins have the function of transporting lipids
throughout the body. Low density lipoproteins are re-
sponsible primarily for the transport of cholesterol with
the protein moiety involved: apolipoprotein (Apo) B 100.
Very low density lipoproteins are responsible for the
transport of triglycerides with the protein moiety in-
volved: Apo E. High density lipoproteins are responsible
for reverse cholesterol transport and play an important
role in being a naturally occurring potent anti-inflamma-
tory and antioxidant agent with the protein moiety in-
volved: Apo A. It is the protein moiety of the lipoproteins
that is modified by the processes of oxidation, glycation,
and glycoxidation with a resultant increase in redox stress
and the production of ROS. Furthermore, the modifica-
tion of the protein moiety is responsible for their reten-
tion within the intima, inducing atherogenesis and thus
atheroscleropathy. [69,70]
(L). Lipotoxicity – specific
Lipotoxicity is also associated with MS, IR, PD, and
T2DM. Unger et al.[71–76] feel this specific lipotoxicity is
attributed to products of the excessive non-beta- (non-mi-Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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tochondrial) oxidative metabolism of FFA in the skeletal
and the myocardial muscle, the liver and the pancreatic is-
lets.
In addition, these toxic metabolic products are thought to
cause the complications of MS, IR, PD, and T2DM by cre-
ating cellular dysfunction and, in time, promoting pro-
grammed cellular death (lipoapoptosis). [74,75] In the
normal state, FFA delivery to non-adipose tissue is closely
regulated to its need for fuel. FFAs normally rise during ex-
ercise and fasting in order to meet metabolic requirements
and thus, homeostasis is maintained. However, as a result
of over-nutrition (western diet), the FFA influx may ex-
ceed FFA usage and FFA non-beta oxidation ensues.
These non-mitochondrial FFA metabolites, which are re-
sponsible for injuring cells, result in lipoapoptosis, in-
clude triglycerides, ceramide, and products of lipid
peroxidation. Ceramide (an amino alcohol with a LCA-
CoA attached to the amino group) has been implicated for
some time in the apoptotic pathway of the T1DM autoim-
mune destruction of beta cells by sphingomyelin degrada-
tion. [77]
Ceramide can be formed in these cells by direct de novo
synthesis from FFAs. [72] Ceramide is responsible for the
induction and activation of NFkappa B. [78]
In the process of developing T2DM, only those beta cells
with the highest fat content give way to the ceramide cas-
cade thus leaving enough functioning beta cells to main-
tain insulin independence but not enough to compensate
for the co-existing insulin resistance with the subsequent
development of impaired glucose tolerance, impaired
fasting glucose and the development of overt T2DM. This
entire process is magnified and progresses due to an in-
tense redox (oxidative stress within the islet and intima
which incorporates and implicates the multiplicative
manifold A-FLIGHT toxicities).
I). Insulin toxicity
Insulin toxicity (hyperinsulinemia, hyperproinsulinemia,
and hyperamylinemia) is associated with MS, IR, PD, and
early T2DM. In late T2DM as beta cell failure develops
there is no longer insulin toxicity. Insulin is known to up-
regulate the number of AT-1 receptors, activate the RAAS,
and be capable of cross talking with the AT-1 receptor. Re-
cently, AT-1 receptors have been identified on the islet
beta cell and the islet endothelial cell.
Thus, hyperinsulinemia can be linked back to the section
"(A). Angiotensin II" with resultant increased redox stress
systemically as well as within the intima and islet as insu-
lin, proinsulin and amylin are all three elevated within the
intima and islet milieu. [20–25]
Endogenous Hyperinsulinemia (eHI) is associated with
MR, IR, PD, and early T2DM. Additionally, eHI is associ-
ated with hypertension and atheroscleropathy (coronary
artery disease). eHI is also associated with elevated FFA,
plasminogen activator inhibitor-1 (PAI-1), elevated sym-
pathetic tone and activity, increased sodium and water re-
absorption leading to volume expansion which leads to
and supports hypertension in the clustering phenomenon
of MS relating to section (H). Hypertension toxicity. Pre-
viously discussed, insulin, proinsulin, and amylin have
been noted to contribute to the elevation of Ang II with in-
creases in renin and aldosterone.
Amylin the fraternal twin of insulin has been shown to in-
duce lipolysis which elevates FFA and links to the sections
on (F), (L), and (T). The reader will note that the various
sections within the A-FLIGHT toxicities interact and play
off one another creating a vicious cycle of promoting re-
dox stress within the intima and islet.
Additionally, it is important to note that increased proin-
sulin concentrations predict death and morbidity caused
by coronary heart disease independent of other major car-
diovascular risk factors. [79,80]
(I). Inflammation toxicity
A new insight into the study of atherosclerotic plaques has
evolved over the past decade and now the accepted role of
inflammation in vulnerable plaque pathology has been
widely accepted in the field of atherosclerology.
Currently, chronic inflammation is gaining momentum
as a prelude to MS, IR, PD, and T2DM.
Increasingly, this quartet in the continuum of the natural
history of diabetes is being accepted by diabetologists and
researchers as a chronic inflammatory disease. [9,81–92]
The four "cardinal signs" of inflammation described by
Aulus C. Celsus in De re medicina in 30 A.D. are: rubor, cal-
or, dolor, and tumor and currently there is a large body of
information that atherosclerotic vulnerable plaques (VP)
fit the above criteria.
Rubor
VPs have a unique increase in angiogenesis of the vasa va-
sorum which act as a FedEx delivery system and thus in-
crease flow for inflammatory cells and injurious substrates
to promote vulnerability at the endothelial extracellular
matrix interface.
Calor
Recently, these VPs have been shown to possess a higher
core temperature.Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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Dolor
There is no direct pain associated with the VP, however,
once it is ruptured the cardiovascular event is quite pain-
ful and the fixed stenotic lesions of atheroscleropathy cre-
ate the painful syndrome of angina pectoris.
Tumor
There is no doubt that there is swelling of even the athero-
ma (outward positive remodeling) as well as encroach-
ment upon the lumen with negative remodeling resulting
in a stenotic lesion which entertains the fifth sign of in-
flammation, functio laesa, inhibited or lost function. Re-
cently, Naghavi M et al. were able to show that these VPs
were more acidic which may be an asset in detecting their
presence in vivo. [93–96] (figure 5)
Inflammation toxicity (with increased redox stress and cy-
tokines) is associated with MS, IR, PD, and early as well as
late T2DM.
The innate inflammatory mediators, TNFalpha and inter-
leukin 6 (IL-6), are tightly associated with central (visceral
– omental) obesity, MS, IR, PD, and T2DM. [97][98,99]
This innate immune system (IL-6 and TNF alpha which
activates the acute phase response) is more ancient and
does not require a previous antigenic stimulus as does
theacquired antigen – antibody related immune system.
Downstream from IL-6 and TNFalpha, elevated white
blood cell count, sialic acid, orosomucoids and the acute
phase reactants: highly sensitive C reactive protein (hs-
CRP), fibrinogen, and serum amyloid A are associated
with the development of T2DM and atheroscleropathy.
Factor VIII, von Willebrand factor (indicating endothelial
cell activation) and activated partial thromboplastin time
have also been implicated in the development of T2DM.
[100]
NFkappa B is associated with redox stress and the isoform
inducible iNOS in the apoptosis of the beta cell in both
T1DM and T2DM. Both NFkappa B and TNFalpha are in-
duced by ROS [60].
The adhesion of the leukocytes to the post-capillary
venule is an important step in the inflammatory process
and the adhesion of the leukocytes to the endothelial cells
is induced by ROS. This effect is abolished by catalase but
not SOD, suggesting that H2O2 and the OH- radical but
not super oxide is involved. ROS treatment of endothelial
cells induce the focal adhesion kinase pp 125 PAK, a cy-
tosolic tyrosine kinase which has been implicated in the
oxidant-mediated adhesion process. [101]
This section and the section (A). Ageing are closely related
as ROS and RNS are widely implicated in the inflammato-
ry and ageing process. [102]
Recently, Syad MA, Pietropaolo M, and colleagues [103]
published a paper entitled: Is type 2 diabetes a chronic in-
flammatory / autoimmune disease? They were able to de-
tect a subset of patients with T2DM in which an acute
phase response seemed to be associated with islet cell au-
toimmunity. They were able to demonstrate that 12 % of
patients age 65 and older had islet cell autoantibodies
(ICA) and GAD. They also were able to detect a significant
increase in fibrinogen (P= 0.005) and C-reactive protein
levels (P= 0.025) in patients with high levels of GAD 65
and/or IA-2 autoantibodies as compared with antibody
negative patients and control subjects. [104]
This group of T2DM has been referred to by Zimmet and
others as latent autoimmune diabetes mellitus in adults
(LADA) [105]
This information points to the presence of the acquired
immune (humoral islet cell autoimmunity) system being
in play in a subset of older as well as younger patients with
T2DM and that this system is significantly associated with
the downstream acute phase reactants of the innate im-
mune system: C-reactive protein and fibrinogen. This
same delicate interplay of the two immune systems may
well be in play in the development of atheroscleropathy as
we know there are autoantibodies to oxidized LDL-C. As
further knowledge emerges regarding these two immune
systems and how they interact we may have an even better
understanding of the complex mechanism of MS, IR, PD,
T2DM, and atheroscleropathy.
The current medical literature has provided us with a
growing body of knowledge in studies of basic science, ep-
idemiology, animal, and even human clinical trials that
implicate inflammation in the pathogenesis of MS, IR,
PD, T2DM and atheroscleropathy with their morbid,
deadly intersection.
The above is information is incomplete and just a small
portion of information was presented to set the stage re-
garding the role of inflammation in the intima and islet.
In summary, there are two common threads that weave
these two diseases (T2DM and accelerated atherosclero-
sis) together, resulting in the complex mosaic fabric of
atheroscleropathy:
Redox stress and inflamation. (figure 6)
It is interesting to note that both HMG CoA Reductase in-
hibitors (statins) and ACE inhibitors and ARBs are having
such a profound effect on non diabetic atherosclerosis
and hypertension and an equal if not greater reduction inCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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events in the treatment of diabetic associated hyperten-
sion, atheroscleropathy, and even delaying or preventing
the development of overt T2DM. (table 9) Note that the
three drug classes all have a direct or indirect positive ef-
fect on inflammation and redox stress. Utilizing the RAAS
acronym may have a positive effect on event outcomes at
the morbid mortal intersection associated with the inter-
weaving threads of redox stress and inflammation which
result in atheroscleropathy.
(G). Glucotoxicity
Glucotoxicity is associated with both type 1 and type 2 di-
abetes mellitus and, thus, the similarly shared multiple
opathies associated strongly with redox stress (figure 7).
There is a major difference between T1DM and T2DM in
regards to atheroscleropathy. In T1DM the atherosclerop-
athy does not start until there is a diagnosis and glucotox-
icity develops acutely. In contrast T2DM is preceded by 5–
10 years of a MS, IR, and PD state consisting initially of
postprandial glucose elevations (IGT) then fasting glucose
elevation.(IFG). Additionally, MS and IR comes with the
attendant A-FLIGHT toxicities. (table 3)
Four subsections are important in this discussion.
I. AGEs were discussed in section (A)
II. Autoxidative reactions
Autoxidative reactions occur as monosaccharides, and
fructose-lysine can spontaneously reduce molecular oxy-
gen.
Figure 7
Glucotoxicity and intimal redox stress injury to the arterial vessel wall in atheroscleropathy initially associated with glucose
elevations post prandial then fasting as in prediabetes (PD). Stages III and IV. Transitioning to overt T2DM on the continuum.
(table 8)
Polyol
Pathway
Reductive Stress
Glucose auto-oxidation Protein Glycation
AGEs
Decreased Antioxidant
Network
Defense Mechanisms
Other Oxidative
Factors A-FLIGHT
ISLET  REDOX STRESS
Redox Stress Injury to the vulnerable Intima
of the Arterial Vessel Wall.
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The reduced oxygen products formed are O2
-, OH-, and
H2O2. Each of these ROS can contribute to damaging lip-
ids and proteins through cross-linking and fragmentation.
[106–108]
The process of combined autoxidation and glycation is
frequently referred to as glycoxidation which is another
common process of protein modification. The ROS from
these reactions serve not only as the source for autoxida-
tion but also fuel the cycle of AGE formation (ROS beget
ROS).
Autoxidation occurs at the site of the protein component
embedded within the LDL cholesterol particle resulting in
glycated LDL and glycoxidated LDL cholesterol which
contribute to its retention just as oxidized LDL is retained
within the intima which initiates and sustains atherogen-
esis and subsequent atheroscleropathy.
Native LDL is not atherogenic and is not retained within
the intima; however, if it becomes modified by oxidation,
glycation, glycoxidation or homocysteinated, it becomes
modified and retained (trapped to adjacent gly-
cosaminoglycans and structural glycoproteins) to initiate,
maintain, and accelerate the atherogenic process within
the intima.
III. The Polyol – sorbitol pathway
The polyol – sorbitol pathway is also driven by an excess
production of glucose. Glucose is converted to sorbitol by
aldose reductase at the expense of NADH/NAD(P)H be-
ing converted to NAD+/NAD(P)+. Sorbitol is then con-
verted to fructose by sorbitol dehydrogenase at the
expense of NAD+ NAD(P)+ being converted to NADH/
NAD(P)H. [60–62]
This reductive stress (pseudohypoxia) of the polyol –
sorbitol pathway thus amplifies the redox stress within
the islet milieu. This singular pathway is of great impor-
tance as it is the major pathway for supplying unpaired
unstable electrons through the process of reduction. This
reductive stress is dependent upon hyperglycemia associ-
ated with both T1DM and T2DM. Postprandial hypergly-
cemia results in reductive stress even before overt T2DM
has developed.
Were it not for the importance of this singular source of re-
ductive stress, this review could have been entitled "Inti-
mal Oxidative Stress".
IV. Glucose scavenging of nitric oxide
Endothelial dysfunction is strongly associated with both
T1DM and T2DM. Brodsky et al. have recently been able
to demonstrate that glucose is capable of directly scaveng-
ing NO resulting in the chemical inactivation of NO. They
were able to conclude that the glucose-mediated NO loss
may directly contribute to hypertension and endothelial
dysfunction in diabetic patients. [109]
The authors were also able to show a glucose-mediated
decline in the lifetime of NO. These findings may have a
direct, deleterious effect of decreasing the naturally occur-
ring antioxidant capability of NO.
Glucotoxicity increases oxidative stress as demonstrated
by increased 8-hydroxy-2'-deoxyguanosine (8-OhdG, a
marker for oxidative stress) found in the urine and mono-
nuclear cells from blood in T2DM patients.
Ihara et al. found higher levels of 8-OHdG and 4-hydroxy-
2-nonenal- (HNE)-modified proteins in pancreatic beta-
cells of GK rats (a model of non-obese type 2 diabetes)
than in control Wistar rats. These levels increased propor-
tionally with age. [110]
Section "(F). Free Fatty Acids" would lead one to believe
that a lipocentric view is of extreme importance and may
be playing the dominant role in beta cell dysfunction and
insulin resistance.
Poitout and Robertson [111] have recently pointed out
(with strong supporting data) that glucotoxicity is a pre-
requisite for lipotoxicity. They propose that chronic hy-
perglycemia (independent of hyperlipidemia) is toxic for
beta-cell function, whereas chronic hyperlipidemia is del-
eterious only in the context of concomitant hyperglyc-
emia. With time, both glucotoxicity and lipotoxicity
contribute to the progressive deterioration of glucose
homeostasis and beta cell dysfunction. Seldom do either
of these two toxicities exist alone in the postprandial clin-
ical setting of MS, IR, PD, and T2DM, and both contribute
to the excess redox stress associated with the other A-
FLIGHT toxicities, having an overall multiplicative effect
within the intima and islet. [111]
Before leaving this section on glucotoxicity it is important
to note that cytosolic production of superoxide [O2'] re-
sults in the activation of protein kinase C, increased for-
mation of glucose-derived advanced glycation products,
and an increased flux through the polyol – sorbitol path-
way. Nishikawa T et al was able to show nicely that by
blocking mitochondrial derived O2' with manganese su-
peroxide dismutase or uncoupling mitochondrial oxida-
tive phosphorylation they were able to prevent the above
cytosolic perturbations. [112] Additionally, Pennathur S
et al were able to demonstrate in the Cynomologus monkey
that streptozotocin induced diabetes resulted in a hy-
droxyl radical-like species which oxidized artery wall pro-
teins. The oxidative products, ortho-tyrosine and meta-
tyrosine correlated strongly with serum levels of glycatedCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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hemoglobin. In these early lesions 3-nitrotyrosine was not
correlated to the glycated hemoglobin. [113]
(H). Hypertension toxicity
Hypertension is associated with increased redox stress and
ROS activity. Furthermore, hypertension is associated
with ROS mediated vascular damage and is closely associ-
ated with the activation of Ang II (see section (A). Angi-
otensin II) and its effect on the vascular NAD(P)H oxidase
superoxide (O2
-) generating enzyme. [26]
Cellular sources of vascular superoxide production are the
endothelial cell, vascular smooth muscle cell and adventi-
tial fibroblasts. The major enzymatic sources are
NAD(P)H oxidase, xanthine oxidase and, paradoxically,
the eNOS enzyme (in the presence of oxidative stress or
deficiency of L-arginine or tetrahydrobiopterin).[114]
It is important to note that glucotoxicity is closely associ-
ated with activation of the RAAS at the local, interstitial
and tissue levels.
Recently, amylin has been implicated as being elevated in
patients who have a positive family history associated
with hypertension and is elevated prior to the onset of hy-
pertension when insulin remains at the normal level.
Thus, amylin levels may become a screening tool for the
development of future essential hypertension. [115]
Hypertension is associated with the clustering phenome-
non of the metabolic syndrome and its importance to the
overall picture of redox stress is not to be underestimated
as it contributes significantly to the overall morbidity and
mortality associated with T2DM. [116,117]
(H). Homocysteine toxicity
The general population of diabetics (T1DM and T2DM)
will, in all probability, have the same amount of gene pol-
ymorphism of the folate-dependent methylene tetrahy-
drofolate reductase gene with subsequent mild to
moderate hyperhomocysteinemia (hHcy) which occurs in
10–15% of the general population. [118–120]
This gene polymorphism is especially important in those
individuals with a decrease in dietary folate. hHcy can be
improved with folate supplementation and can improve
endothelial-dependent endothelial cell dysfunction.
[121]
Homocysteine (Hcy) is not usually elevated as a direct re-
sult of diabetes unless there is an associated development
of impaired renal function. As nephropathy develops,
there is an associated elevation of total Hcy associated
with a decline in glomerular filtration rate. [122]
This plays an extremely important role for those diabetic
patients on dialysis. [123] hHcy is thought to induce an
oxidative inactivation of endothelial nitric oxide, in part
by inhibiting or consuming the expression of cellular glu-
tathione peroxidase (GPx). In heterozygous cystathionine
beta-synthase deficient -/+ mice, Weiss et al. were able to
restore endothelial cell function by increasing cellular thi-
ol and reducing glutathione pools and increasing GPx ac-
tivity with restoration of the endothelial function. [124]
The ensuing cellular redox stress is magnified and total
Hcy consumes NO by the indirect process of O2
- convert-
ing NO to toxic peroxynitrite (ONOO-).
In addition to ONOO- formation, NO in conjunction
with thiols and oxygen radicals generate nitrotyrosine and
nitroarginine which compete for the substrate eNOS in a
feedback mechanism, limiting further NO generation.
[125–127] As a result, there is endothelial cell dysfunc-
tion, endothelial cell toxicity and endothelial cell loss, in-
creased ROS, increased ONOO- and decreased NO
associated with hHcy. [128] hHcy is multiplicative in na-
ture and even though its effects may occur later in T2DM
than the other associated toxicities, it has a devastating ef-
fect on endothelial cell function.
Presently, we know there are other toxicities operating
within the renal glomerulus producing microalbuminuria
(reflecting endothelial cell dysfunction and damage) at a
stage prior to the declining glomerular filtration rate re-
sponsible for hHcy.
A recent clinical study by Maejima et al.[129] revealed sig-
nificant elevated levels of ONOO- peroxynitrite (by Griess
method) in 126 T2DM patients as compared to 76 non-
diabetic controls. ONOO- levels were related to the pres-
ence of hypertension and advanced microvascular com-
plications. In addition, ONOO- correlated positively with
elevations in AGEs and serum lipid peroxide.
These data support the hypothesis that decreased en-
dothelium-dependent vasodilatation in diabetic subjects
is associated with the impaired action of NO secondary to
its consumption from redox stress rather than decreased
NO production from vascular endothelium. Clinically,
abnormal NO metabolism is related to advanced diabetic
microvascular complications. Zhang et al.[130] were able
to demonstrate that increased concentrations of Hcy re-
sulted in a decreased NO response to bradykinin and L-ar-
ginine.
They were able to show that Hcy stimulated the formation
of superoxide anions and peroxynitrite with increased lev-
els of nitrotyrosine. The addition of 5-methyltetrahydro-
folate restored NO responses to bradykinin and L-arginineCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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Table 8: Courtesy [8,9,53] The five stages of T2DM: the natural progressive history of T2DM
I. LATENT STAGE:[EARLY]
Insulin Resistance:
• Genetic Component
• Environmental component. Modifiable: obesity/sedentary life style. Nonmodifiable: aging.
Beta Cell Defect: (Dysfunction)
• Genetic ....... Abnormal processing, storage or secretion.
• Intracellular/extracellular amylin fibril toxicity. Abnormal processing, storage or secretion.
Intra-Islet Endothelial Absorptive Defect:
• Heparan sulfate proteoglycan (HSPG) PERLECAN of the capillary endothelial cells avidly attracts amylin (IAPP) and 
the islet amyloid forms an envelope around the capillary. This is in addition to the increase in the basement membrane 
associated with the pseudohypoxia (associated with glucotoxicity) and the redox stress within the capillary.
II. TRANSITION STAGE:[MIDDLE]
Persistent Hyperinsulinemia
Persistent Hyperamylanemia
• Continued remodeling of the endocrine pancreas (amyloid).
• Beta cell displacement, dysfunction, mass reduction and diffusion barrier.
III. IGT STAGE (Impaired Glucose Tolerance):[LATE] "Pre-diabetes" Human Health Services (HHS) and American 
Diabetes Association (ADA) term.
[Start treatment at this time]
[Diagnose earlier: rejuvenation of the 2 hour glucose tolerance blood sugar 140–199 mg/dL]
• Increased insulin resistance [Feeds forward] > Glucotoxicity [Feeds forward] > Insulin resistance [Feeds forward] > 
Glucotoxicity: creating a vicious cycle.
• Islet amyloid. Increasing beta cell defect. Loss of beta cell mass with displacement. (Remodeling of islet architecture 
including extracellular matrix). Beta cell loss centrally.
IV. IFG STAGE (Impaired Fasting Glucose):[LATER] "Pre-diabetes" Human Health Services (HHS) and American 
Diabetes Association (ADA) term.
[Blood sugar ranging 110–126 mg/dL]
[Impaired hepatic glucose production]
• Increasing global insulin resistance (hepatic) with subsequent gluconeogenesis. Feeding forward in the vicious cycle to 
accelerate insulin resistance globally.
V. OVERT STAGE:[TO LATE]
[50% loss of beta cell function]
Va, Vb, Vc. Phases I, II, III: mild, moderate/severe, complete. Use medications that do not increase insulin or amylin. 
Use combination therapy. Start treatment at stage III-IV (IGT-IFG).
• Paradigm Shift. Start treatment at the earlier stage of IGT.
Table 9: Courtesy [8,9,53] The RAAS acronym: for the prevention and treatment of redox stress in atheroscleropathy and stablization 
of the vulnerable intima and islet in T2DM
R Reductase inhibitors (HMG-CoA). Decreasing modified LDL cholesterol, i.e. oxidized, acetylated LDL choles-
terol. Improving endothelial cell dysfunction. Thus, decreasing the oxidative stress to the arterial vessel wall and 
the islet. Redox stress reduction.
AA C E i -prils. ARBS-sartans. Both inhibiting the effect of angiotensin-II locally as well as systemically. Affecting 
hemodynamic stress through their antihypertensive effect as well as the deleterious effects of angiotensin II on 
cells at the local level – injurious stimuli. Decreasing the A-FLIGHT toxicities. Plus the direct/indirect antioxi-
dant effect within the islet and the arterial vessel wall. Redox stress reduction.
Aspirin antiplatelet, anti-inflammatory effect.
AA g g r e s s i v e  control of diabetes. Decreasing modified LDL cholesterol, i.e. glycated LDL cholesterol. Improving 
endothelial cell dysfunction. Also decreasing glucose toxicity and the redox stress to the intima and pancreatic 
islet. Aggressive control of Hcy with folic acid with its associated additional positive effect on re-coupling of the 
BH4 cofactor with the eNOS reaction to produce eNO. Redox stress reduction.
SS t a t i n s . Improving plaque stability (pleiotropic effects) independent of cholesterol lowering. Improving endothe-
lial cell dysfunction and preventing the angiogenesis associated with arterial vascular remodeling which destabilizes 
the unstable atherosclerotic plaque. Plus, the direct/indirect antioxidant anti-inflammatory effects within the islet 
and the arterial vessel wall promoting stabilization of the unstable, vulnerable islet and the arterial vessel wall. 
Style: Lifestyle modification: Stop smoking, lose weight, exercise, and change eating habits. Redox stress 
reductionCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
Page 22 of 27
(page number not for citation purposes)
agonists. In addition, scavengers of peroxynitrite and SOD
mimetics reversed the Hcy-induced suppression of NO
production by endothelial cells. Concentrations of Hcy
greater than 20 M produced a significant indirect sup-
pression of eNOS activity without any discernible effects
on its expression.
Li et al. just published an article showing an unexpected
effect of Hcy-induced oxidative stress resulting in an in-
crease of 3-hydroxy-3-methylglutaryl coenzyme A reduct-
ase in vascular endothelial cells, as well as decreasing
endothelial NO.
They were also able to demonstrate that "statins" (Table
7) were able to increase NO as well as decreasing cellular
cholesterol. [131]
Stuhlinger MC et al were able to demonstrate that Hcy im-
pairs the nitric oxide synthase pathway. Homocysteine in-
hibits dimethylarginine dimethylaminohydrolase
(DDAH) which is responsible for degrading ADMA.
This effect of Hcy causes the endogenous inhibitor of ni-
tric oxide synthase, ADMA to accumulate and inhibit ni-
tric oxide synthesis. This effect helps to explain the
deleterious effect of Hcy on the endothelial cells ability to
promote vasodilatation and associated endothelial cell
dysfunction with decreased NO synthesis. [132]
(T). Triglyceride toxicity
Multiple lipases (intestinal, muscular – both skeletal and
cardiac-, adipose, and hepatic) are responsible for the dy-
namic flux between the long chain fatty acids (LCACoA
esters) and the glycerol molecular backbone of the triglyc-
erides (see section (F). Free Fatty Acids").
Hypertriglyceridemia certainly plays a role in toxicity re-
garding the development of redox stress, not only its role
in lipotoxicity and FFA toxicity discussed previously, but
independently as its own marker of toxicity. There is a
close association of hypertriglyceridemia and the athero-
genic small dense LDL cholesterol particles which are
more likely to be oxidized and contribute to redox stress.
This condition is central to the lipid triad [133].
We need to recall that Apo E is responsible for carrying
this lipid fraction and that the Apo E -/- knockout mouse
develops atherosclerosis at an accelerated rate. We need to
also bear in mind that gene polymorphism may play a
role in the development of ADIA since Apo E is an impor-
tant part of all amyloid formation and stabilization. Kahn
et al. were able to demonstrate in the human islet amyloid
polypeptide transgenic mouse model that these mice did
not develop islet amyloid unless fed a high fat diet [134].
Stored neutral triglycerides provide the substrate for FFA
production which can be immobilized immediately by ex-
ercise or stress induced lipolysis.
When these are stored in ectopic non-adipose cells such as
the cardiac and skeletal myocyte, the endothelial cell or
the islet beta cell, they are capable of causing cellular dys-
function or lipoapoptosis as discussed in the sections "(F).
Free fatty acids" and "(L). Lipotoxicity – Specific".
As stated earlier in this paper, it is difficult to separate
these three moieties as they are closely interconnected
with each other and within the manifold A-FLIGHT toxic-
ities.
Redox stress and matrix metalloproteinases
Elevated redox stress is associated with an increase in ma-
trix metalloproteinase (MMP) activity, especially the in-
ducible MMP-9 [135].
This would be associated with an increase in extracellular
matrix (ECM) remodeling and would contribute to in-
creased intima media thickness within the arterial vessel
wall. This would accelerate the process underlying the
similar mechanism of AGEs with a stiffening and de-
creased compliance of the arterial vessel wall which would
contribute to diastolic dysfunction of the arterial vessel
wall. The acceleration of the stiffness of the arterial vessel
wall would contribute to hypertension, specifically systo-
lic hypertension. This mechanism may be in play in the
clustering of hypertension in the metabolic syndrome.
Cells are dependent on integrin matrix ligand binding
sites and MMP-9 is a basement membrane degrading en-
zyme. Cells are constantly re-establishing new integrin
matrix binding sites. However, if there is a complete dis-
connection of integrin matrix binding sites due to a robust
increase in MMP-9, the cell may undergo apoptosis.
MMP-9 was recently shown to be elevated in diabetes mel-
litus and, in addition, the role of redox stress was shown
to play an important role [135].
A robust activation of MMP-9 may result in a complete
disconnection of the beta cell and the surrounding ECM
with resultant apoptosis. Recently, in our laboratory, we
have been able to demonstrate decreased endothelial cell
density with increased apoptosis of endothelial cells in
the hearts of mice treated with alloxan vs. controls.
We were also able to show a decrease in NO and an in-
crease in peroxynitrite and ROS in these same animals
thus, linking the importance of cellular apoptosis, MMP-
9 and redox stress. We then compared these findings of al-
loxan-induced diabetes in MMP-9 knockout mice to al-
loxan-induced diabetes in the wild type. Alloxan-inducedCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/3
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diabetes MMP-9 -/- mice did not have induced apoptosis
and did not have a decrease in endothelial cell density
when compared to wild type alloxan-induced diabetes
(unpublished data).
These findings may apply to the beta cell within the islet,
as all cells require an integrin matrix binding for survival.
The MMP-9 may also decrease the larger size amylin de-
rived islet amyloid fibrils to the more intermediate size
toxic amyloid particles and contribute to apoptosis as de-
scribed by Janson et al.[136] (Table 5).
MMP-9 has also been shown to be elevated in laminitic
horses having digestion of the basement membranes with
resultant separation of the epidermal and dermal lamina.
[137] These same processes within the islet could be re-
sponsible for a loss of intracapillary endothelial cells
which would decrease the rate at which they could pick up
newly synthesized insulin and transport it to the systemic
circulation, and provide a mechanism for the delay in first
phase insulin secretion which is typical of T2DM and even
impaired glucose tolerance.
MMP-9 may even play a role in the clearing of ECM in or-
der to allow for the space-occupying lesion of ADIA dep-
osition. Redox stress (signaling) activates MMPs (Table 5).
Conclusion
Throughout this review, we have tried to remain focused
on the relationship between redox stress and ROS in the
intima and at times the islet, and how these two interact
with the multiplicative effect of the A-FLIGHT toxicities of
MS, IR, PD, and overt T2DM to induce atheroscleropathy.
The reader will note that redox stress and ROS operate
through similar mechanisms and will operate in a similar
fashion in other chronic disease states such as chronic in-
flammatory diseases (pancreatitis, rheumatoid arthritis,
ulcerative colitis, Crohn's), ageing, cancer, ischemia/
ischemia-reperfusion injury, hypertension, diastolic/
systolic dysfunction, congestive heart failure, diabetic and
nondiabetic nephropathy and neurodegenerative diseas-
es.
When redox homeostasis transitions to redox stress, redox
signaling ensues in all tissues and organs regardless of the
multiple similar or dissimilar etiologies.
Redox stress is a redox signaling system. [101,138]
Reflections and future directions
An article entitled "Diabetes as a manifold disease" (pre-
viously published in the February 8th, 1902 issue of JA-
MA) was reprinted in the February 13th, 2002 issue of
JAMA, in the section on 100 years ago. [139,140]
T2DM and associated atheroscleropathy remain a hetero-
geneous and manifold disease not only in their etiology
but also in their manifold toxicities associated with MS,
IR, PD, and T2DM.
In 1902, the author (unknown) could not have envi-
sioned the exponential growth of T2DM and atheroscle-
ropathy we are currently experiencing.
Just as this author pointed to a new concept, we have at-
tempted, in this review, to outline the important contem-
porary concept of intimal redox stress and the rusting –
rancid intima within vulnerable atherosclerotic plaques.
Treatment and potential prevention of these diseases can
be accomplished through global risk reduction of the
manifold toxicities by using the currently available treat-
ment modalities we now have at our disposal. [141]
If the current trend continues (due to the current epidemic
of our adolescent youth and the aging baby boom gener-
ation) these patients are going to be seen in our offices
with increasing frequency.
Recently, Dagogo-Jack S discussed primary prevention of
diabetes, secondary prevention (of diabetic complica-
tions), and tertiary prevention (of morbidity and mortali-
ty from established diabetic complications) utilizing
multiple drug targets in the management of T2DM.
Currently, a focus on global risk reduction is necessary for
a more complete approach by physicians providing care
for the diabetic patient. [142,143] By aggressively reduc-
ing the elevated substrates producing the A-FLIGHT toxic-
ities and ROS (table 3) and using the simple RAAS
acronym (table 9) we may be able to restore our individ-
ual, endogenous, potent, antioxidant network. A better
understanding of redox stress and redox homeostasis will
enable eac h of us to develop a shift in the treatment par-
adigm for the quartet of MS, IR, PD, T2DM, and the asso-
ciated cardiovascular atheroscleropathy due to the loss of
metabolic and redox homeostasis.
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nitric oxide; iNOS: inducible nitric oxide synthase;
ISTAPs: intermediate sized toxic amyloid particles; LCA-
CoA: long chain acyl-Coenzyme A; NFkappa B: nuclear
factor kappa B; nNOS: neural nitric oxide synthase; NO:
nitric oxide; NOS: nitric oxide synthase; O2-: superoxide;
OH-: hydroxyl radical; ONOO-: peroxynitrite; RAGE: re-
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